【PitchBook】2024年肿瘤健康科技VC市场快照-2024

Summary of Oncology Healthtech VC Market

Core Content

The oncology healthtech sector is a rapidly evolving area of healthcare innovation, driven by the need for more effective cancer screening, diagnostics, and treatment solutions. Cancer remains a leading cause of death globally, contributing to about one-sixth of all deaths. The economic burden of cancer is significant, with an estimated cost of over $25 trillion over the coming decades. Despite declining mortality rates due to advances in screening and treatment, the number of new cancer cases remains steady, and there has been a recent rise in cancer rates among younger populations.

Market Size and Growth

• Global Market Size: The global oncology healthtech market is estimated to be around $250 billion.
• Cancer Screening: This category is the largest market opportunity, with a global market size of approximately $100 billion and over $40 billion in the US alone.
• Market Growth: Assuming a conservative compound annual growth rate (CAGR) of 4%, the oncology healthtech market is projected to expand to over $400 billion within the next decade.

Key Opportunities

1. Cancer Screening Innovations:

   • Liquid biopsy and image-based detection technologies are expected to drive demand for new cancer screening products.
   • Regular multicancer detection is set to become part of the standard of care in health screening.

2. Diagnostics and Life Sciences:

   • Tissue Biopsy & Pathology: A significant market with global sizes exceeding $10 billion.
   • Imaging Equipment: Another large market with global sizes exceeding $10 billion.
   • Precision Oncology: Companies like 和瑞基因 (Berry Oncology) and BostonGene.com are leading in this space.

3. Digital Health:

   • Care Coaching: Companies such as LEAL HEALTH and outcomes4Me are making strides in this area.
   • Care Coordination & Navigation: Thyme Care and OncoHealth are notable players.
   • Diagnostic Devices: DermoSensor and IONIO SCIENCE are contributing to this segment.

4. Therapeutics and Drug Delivery:

   • Companies like Attovia and others are exploring new methods of drug delivery and treatment.

5. Radiation Therapy:

   • Innovations in this area are expected to play a key role in cancer treatment advancements.

6. Research & Clinical Trials:

   • Companies such as iYERATIVE HEALTH and Aster are contributing to the research and clinical trial landscape.

Key Risks and Considerations

• Market Saturation: Much of the low-hanging fruit in cancer care innovation has already been achieved, making further growth challenging.
• Regulatory Hurdles: The healthcare industry is heavily regulated, and navigating these can be complex for startups.
• Competition: The market is dominated by established players, making it difficult for new entrants to gain market share.
• Technological Barriers: High development costs and the need for advanced technology can be significant obstacles.

VC Activity

• Funding Trends: Oncology healthtech companies have raised over $16 billion in venture capital since 2020, peaking at $5 billion in 2021.
• Deal Count Reduction: There has been a sharp decline in the number of deals since 2021, consistent with broader healthtech trends.
• Notable Funding Rounds:
  • Insightec: $150 million late-stage round
  • BillionToOne: $130 million Series D
  • Thyme Care: $95 million Series C

Market Segmentation

The VC-backed oncology healthtech companies are segmented into the following categories:

1. Patient Monitoring
2. Devices & Implants
3. Cardiac Imaging
4. Chronic Condition Management & Prevention
5. Biopharmaceuticals

Conclusion

The oncology healthtech market presents substantial opportunities due to the growing demand for advanced cancer screening and diagnostic technologies. However, it also poses significant challenges, including market saturation, regulatory hurdles, and intense competition. Startups must navigate these challenges carefully to find successful exit opportunities or to carve out a niche in this evolving landscape.